MGUS: predicting the risk of progression

Tarek H Mouhieddine, MD, Dana-Farber Cancer Institute, Boston, MA, describes the rationale for the improved identification of high-risk patients who may be appropriate for novel clinical interventions to prevent progression or eradicate premalignant clones prior to the development of overt multiple myeloma (MM) at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.